Findings

What do systematic reviews say?

45 questions · 45 findings · 3 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 15.6%GRADE not reported 0 · 0%Very low 15 · 33.3%Low 18 · 40%Moderate 5 · 11.1%High 0 · 0%

Summary of findings ‐ Inhaled mannitol vs dornase alfa

FEV1 % predicted · children and young adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Inhaled mannitol vs dornase alfa

FVC · children and young adults with CF

It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
MD 0.14
231 participants
Very low

Summary of findings ‐ Inhaled mannitol vs dornase alfa

Lung function: FEF25‐75 mL/s (percentage change from baseline) · children and young adults with CF

It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FEF25-75 mL/s (percentage change from baseline) compared with dornase alfa (very low certainty).

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low

Summary of findings ‐ Inhaled mannitol vs dornase alfa

Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young adults with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

Lung function: FEV1 mL (percentage change from baseline) · children and young adults with CF

It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEV1mL (percentage change from baseline) compared with dornase alfa (very low certainty).

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

FEV1 % predicted · children and young adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

FVC · children and young adults with CF

It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

Lung function: FEF25‐75 mL/s (percentage change from baseline) · children and young adults with CF

It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEF25-75 mL/s (percentage change from baseline) compared with dornase alfa (very low certainty).

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low

Hypertonic saline vs mannitol

FEV1: short term · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Hypertonic saline vs mannitol

FEV1 (L) · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs mannitol

LCI · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs mannitol

All‐cause mortality · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs mannitol

Measures of sputum clearance · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Hypertonic saline vs mannitol

Pulmonary exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs mannitol

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Dornase alfa vs mannitol

FEV1 · children with cystic fibrosis

Dornase alfa showed no clear difference in mean absolute change in FEV1 (L) at 3 months compared with mannitol (low certainty).

1 finding from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
MD 0.02
231 participants
Low

Dornase alfa vs mannitol

FVC · children with cystic fibrosis

Dornase alfa showed no clear difference in mean absolute change in FVC (L) at 3 months compared with mannitol (low certainty).

1 finding from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Low

Dornase alfa vs mannitol

QoL · children with cystic fibrosis

Dornase alfa may leads to higher change in quality of life ‐ CFQ‐R at 3 months compared with mannitol (low certainty).

1 finding from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
MD 10.61 [0.27, 20.95]
231 participants
Low